Loading stock data…
JAGX
$2.82+0.09 (+3.30%)
Pre-Market$2.82+0.00 (+0.00%)· Last close Jun 9
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Jaguar Health, Inc. in the Healthcare sector is trading at $2.67 with a market capitalization of $2M. Wall Street consensus targets $262.50 (1 analysts), implying a +9731.5% move over the next 12 months. The stock is currently near its 52-week low of $2.53, remaining 92.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +9731.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 32) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $20.25M↑ | $3.23M↑ | $3.08M↑ | $2.98M↑ | $2.21M |
| Gross Profit | $19.09M↑ | $1.03M↓ | $2.55M↑ | $2.45M↑ | $1.70M |
| Operating Income | $10.18M↑ | -$20.44M↓ | -$7.24M↑ | -$8.01M↑ | -$9.42M |
| Net Income | $8.85M↑ | -$23.06M↓ | -$9.50M↑ | -$10.41M↑ | -$10.46M |
Peer Comparison
JNJUNHPFE
Fundamentals
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The com...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.04M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.10
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
240.66%
Volume
Today's trading volume
25,961
Recent News
Jaguar Health Inc (JAGX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...
Jaguar Health Inc (JAGX) reports an 816% revenue increase, driven by strategic out-licensing and promising clinical advancements.
Jaguar Health (JAGX) Q3 2025 Earnings Transcript
Need a quote from a Motley Fool analyst? Before I turn the call over to management, I'd like to remind you that management make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends, product initiatives, including products in the development stage, which may achieve scientific objectives or meet stringent regulatory requirements.
Jaguar (JAGX) Q4 2025 Earnings Transcript
Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information that reflects the basis upon which Company Management assesses and operates the business. Lisa, the floor is yours. Lisa Conte: Thanks very much, Melissa, and thank you, everybody.
Jaguar Health Inc (JAGX) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ...
Jaguar Health Inc (JAGX) reports a 5% revenue increase and a transformative partnership, despite facing operational losses and regulatory hurdles.
BC-Most Active Stocks
Tryhard Holdings Ltd. 28,780,305 8.03